Latest news
Osteosarcoma ADC breakthrough sparks race as SOT106 readies trials and deals - CHOSUNBIZ - ChosunbizChosunbiz · Thu, 06 Aug 2026 21:01:00 GMTFrom licensing deals to patients: LigaChem and ABL Bio shift focus to clinical proof - koreabiomed.comkoreabiomed.com · Wed, 05 Aug 2026 07:12:03 GMTFierce Pharma Asia—Legend CEO exits; Merck’s hush-hush PD-1xVEGF plan; Otsuka’s novel ADHD nod - Fierce PharmaFierce Pharma · Fri, 31 Jul 2026 07:00:00 GMTRisvutatug Rezetecan Improves PFS in Phase 3 Osteosarcoma Trial - Targeted OncologyTargeted Oncology · Thu, 30 Jul 2026 07:00:00 GMTGSK’s ADC prospects brighten further with Hansoh’s second Phase III triumph - Clinical Trials ArenaClinical Trials Arena · Wed, 29 Jul 2026 07:00:00 GMTGSK plc (NYSE: GSK) sees Ris-Rez hit phase III goal in relapsed osteosarcoma - Stock TitanStock Titan · Tue, 28 Jul 2026 17:04:21 GMTRis-Rez Hits PFS End Point in Phase 3 Osteosarcoma Trial - CancerNetworkCancerNetwork · Tue, 28 Jul 2026 16:08:35 GMTGSK partner Hansoh reports another phase 3 win for priority ADC - Fierce BiotechFierce Biotech · Tue, 28 Jul 2026 12:20:00 GMT